Tissue Therapies, Ltd., signs 2nd cGMP manufacturing contract with QSV Biologics, Ltd., for Synthetic Vitronectin and Chimeric VitroGro(R)-1
August 23, 2006
EDMONTON, Aug. 22 /CNW/ - QSV Biologics (QSV), Ltd. Edmonton, Canada, announced today that they have signed a 2nd contract with Tissue Therapies Limited (ASX: TIS) of Brisbane, Australia. This contract is for the cGMP manufacture of clinical quantities of synthetic Vitronectin (one of the components of the VitroGro(R) platform for accelerated wound healing) and a single protein, chimeric form of VitroGro(R), called VitroGro(R)-1. The VitroGro(R)-1 protein combines the active regions of the multiple protein components of VitroGro(R). These are some of the essential materials that Tissue Therapies will use in preclinical and clinical trials early next year. Under the agreement, QSV will be responsible for technology transfer and cGMP production in QSV's licensed manufacturing facility. Terms of the final manufacturing contract remain confidential.
Dr. Graeme Macaloney, QSV Founder & CEO said: "This represents repeat business with Tissue Therapies whereby we are now making several products for them. The high productivity cell culture manufacturing processes used for these products differ from the earlier processes that we have been developing for Tissue Therapies, but represent processes that our staff are experienced to deal with".
Dr. Steven Mercer, Tissue Therapies CEO said: "QSV earned this extra business with their reliable, efficient and timely communications throughout all phases of delivering contract manufacturing services and their track-record for delivering on time and within budget. VitroGro(R)-1 represents a novel line of innovative chimeric products to be incorporated in to our VitroGro(R) platform, while Vitronectin, will be used in other multiprotein formulations of VitroGro(R). I have great confidence that these ground-breaking products are in safe hands with QSV".
Tissue Therapies Ltd. has worldwide exclusive rights to commercialise VitroGro(R), a platform technology developed by tissue engineering experts at the Institute for Health and Biomedical Innovation at Queensland University of Technology for enhancing cell growth and migration. VitroGro(R) has particular commercial applications in wound healing, tissue regeneration and cell culture. Tissue Therapies is developing more effective medical treatments for wounds and burns, integration of orthopaedic and medical implants, and other applications such as cosmeceuticals. Tissue Therapies also provides cell culture reagents to enhance the growth of mammalian cells for emerging cell-based therapies, along with research and industrial cell culture markets internationally. For further information please visit: www.tissuetherapies.com.
QSV Biologics, Ltd., is one of an elite group of international cGMP biologics contract manufacturer (CMO) providing microbial fermentation, mammalian & insect cell culture, and purification services. QSV's facility has a 10 yr track-record including an Establishment License from Health Canada for manufacturing clinical trial and commercial biologics that is recognised under a Mutual Recognition Agreement with the European Union, Switzerland & Australia. QSV was the sole recipient of the prestigious international Frost & Sullivan "Customer Value Enhancement Award" in 2005. QSV's clientele span three continents and develop protein therapeutics, monoclonal antibodies, vaccines & diagnostics. As a dedicated CMO with no competing products of its own, QSV builds value for its clients by producing quality products in a timely manner. Hence its acronym: QSV: Quality & Speed build Value. For more info., please visit: www.qsvbiologics.com.
For further information:
Richard Hetrick
Director of Business Development
QSV Biologics, Ltd.
Ph: (780) 438-5722
E-Mail: RHetrick@QSVBiologics.com
